Allogene Therapeutics, Inc. (ALLO): Price and Financial Metrics


Allogene Therapeutics, Inc. (ALLO): $26.10

0.34 (+1.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ALLO Stock Price Chart Interactive Chart >

Price chart for ALLO

ALLO Price/Volume Stats

Current price $26.10 52-week high $46.85
Prev. close $25.76 52-week low $23.30
Day low $25.36 Volume 905,200
Day high $26.12 Avg. volume 1,057,386
50-day MA $29.48 Dividend yield N/A
200-day MA $32.49 Market Cap 3.69B

Allogene Therapeutics, Inc. (ALLO) Company Bio


Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is based in South San Francisco, California.


ALLO Latest News Stream


Event/Time News Detail
Loading, please wait...

ALLO Latest Social Stream


Loading social stream, please wait...

View Full ALLO Social Stream

Latest ALLO News From Around the Web

Below are the latest news stories about Allogene Therapeutics Inc that investors may wish to consider to help them evaluate ALLO as an investment opportunity.

The Bottom Is in for These 3 Stocks? Analysts Say ‘Buy’

We all want to build a profitable portfolio – but if you’re new to the markets, and starting from scratch, where do you begin? It’s tempting to buy into the big names, the companies that have been making waves and generating headlines. Tempting, but probably not the best idea. These companies have already made their splash; while they will continue to bring returns, they might not be the best choice for a retail investors looking to expand a return-oriented portfolio. Start by looking low. Not at down-and-out stocks, but at fundamentally sound equities that are trading at recent low prices.

Michael Marcus on TipRanks | June 7, 2021

Why Is Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | June 4, 2021

Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology

ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL StudiesResults from Most Recent Data Discussed at Allogene’s CD19 Forum Demonstrated Six Month Complete Response (CR) Rate of 36% in CAR T Naïve LBCL Patients Treated with ALLO-501 Longest Ongoing CR at 15 Months in Both Large B Cell Lymphoma (LBCL) and Follicular Lymphoma (FL)Overall Response Rate (ORR) of 75

Yahoo | June 4, 2021

Could This Small Biotech Stock Make Waves For Gilead, Novartis?

Allogene said its donor cell-derived cancer treatment was successful for six months. Could it take on Gilead and Novartis?

Yahoo | May 20, 2021

Cancer Biotechs Are on the Move in Advance of Big Conference

Dozens of companies released data in advance of the American Society of Clinical Oncology gathering, which begins June 4.

Yahoo | May 20, 2021

Read More 'ALLO' Stories Here

ALLO Price Returns

1-mo -3.12%
3-mo -32.17%
6-mo -6.79%
1-year -35.54%
3-year N/A
5-year N/A
YTD 3.41%
2020 -2.85%
2019 -3.53%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 2.5656 seconds.